Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Eli Lilly’s Taltz Beat Stelara in Late-Stage Study

By Ryan Bushey | March 6, 2017

Eli Lilly’s grip on the psoriasis treatment space could be getting stronger.

The company reported results from a Phase 3 study showing that Taltz (ixekizumab) produced significantly higher response rates in patients with moderate-to-severe plaque psoriasis compared to Johnson & Johnson’s Stelara.

Investigators gave patients randomized doses of Stelara or Taltz for a total of 52 weeks. Stelara was either administered as a 45 mg or 90 mg weight-based dosing whereas the other group of patients received an initial subcutaneous injection of 160 milligrams of Taltz followed by an 80mg SC injection once every two weeks for 12 weeks, then 80mg every four weeks.

By week 24, the study completed its primary endpoint when an approximate 83 percent of patients taking Lilly’s treatment reached 90 on the Psoriasis Area Severity Index (PSAI), the metric used to assess the extent and severity of the skin condition, compared to 59 percent taking the Stelara regimen.

Also, Lilly’s announcement noted about 49 percent of patients taking Taltz reached 100 on the PSAI scale versus 23.5 percent in the Stelara group.

“For many years, achieving PASI 75 – or 75 percent improvement in skin plaques – has been the standard treatment goal for moderate-to-severe plaque psoriasis,” said lead study author and professor Dr. Kristian Reich, Ph.D., in a statement regarding the results.

“The data of the IXORA-S study is significant, as it demonstrates both high levels of skin improvement for patients treated with Taltz, consistent with pivotal Phase 3 trials, as well as higher response rates over Stelara, which is one of the most frequently used biologics in the treatment of moderate-to-severe plaque psoriasis,” he continued.

These findings could bolster Taltz’s blockbuster sales potential as well.

A report from research and consulting firm GlobalData released last year predicts Taltz could generate sales in excess of $1 billion in the US and Europe by 2022 due to factors like high safety and efficacy profiles along with a convenient dosing schedule.

Researchers presented these findings at the annual American Academy of Dermatology meeting taking place in Orlando, Florida.


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE